Cetuximab biosimilar - PlantForm Corporation

Drug Profile

Cetuximab biosimilar - PlantForm Corporation

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PlantForm Corporation
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Head and neck cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Head-and-neck-cancer in Canada (Parenteral)
  • 18 Sep 2013 Cetuximab biosimilar - PlantForm Corporation is available for licensing as of 17 Apr 2013. http://www.plantformcorp.com/
  • 30 Sep 2012 Preclinical trials in Head and neck cancer in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top